TSE:CTX Crescita Therapeutics (CTX) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free CTX Stock Alerts C$0.44 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's RangeC$0.44▼C$0.4450-Day RangeC$0.37▼C$0.4652-Week RangeC$0.36▼C$0.73Volume23,000 shsAverage Volume16,699 shsMarket CapitalizationC$8.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Crescita Therapeutics alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Crescita Therapeutics Stock (TSE:CTX)Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.Read More CTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTX Stock News HeadlinesMay 8, 2024 | finance.yahoo.comCrescita Reports First Quarter 2024 ResultsApril 18, 2024 | seekingalpha.comCTNM Contineum Therapeutics, Inc.May 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.March 13, 2024 | finance.yahoo.comCrescita Reports Q4 and Fiscal 2023 ResultsFebruary 17, 2024 | morningstar.comCrescita Therapeutics Inc CTXDecember 14, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Wednesday (CTX)November 8, 2023 | finance.yahoo.comCrescita Reports Third Quarter 2023 ResultsNovember 4, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Thursday (CTX)May 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.September 30, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Friday (CTX)September 1, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Tuesday (CTX)August 9, 2023 | finance.yahoo.comCrescita Reports Second Quarter 2023 ResultsAugust 6, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Monday (CTX)July 29, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Friday (CTX)July 18, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Monday (CTX)June 8, 2023 | finance.yahoo.comSubdued Growth No Barrier To Crescita Therapeutics Inc.'s (TSE:CTX) PriceJune 1, 2023 | finance.yahoo.comCroma-Pharma: Launch of topical anaesthetic Pliaglis® in EuropeMay 11, 2023 | finance.yahoo.comCrescita Reports First Quarter 2023 ResultsApril 15, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Friday (CTX)April 12, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Tuesday (CTX)April 11, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Thursday (CTX)April 8, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Wednesday (CTX)April 6, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Wednesday (CTX)March 18, 2023 | seekingalpha.comCrescita Therapeutics GAAP EPS of C$0.06, revenue of C$6MMarch 15, 2023 | finanznachrichten.deCrescita Therapeutics Inc. Reports Q4 and Fiscal 2022 ResultsMarch 15, 2023 | msn.comCrescita Therapeutics GAAP EPS of $0.06, revenue of $6MMarch 15, 2023 | markets.businessinsider.comCrescita Therapeutics Q4 Profit Rises, But Revenues DeclineSee More Headlines Receive CTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescita Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CTX CUSIPN/A CIKN/A Webwww.crescitatherapeutics.com Phone+1-905-6734295FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-1,990,000.00 Net Margins-11.33% Pretax MarginN/A Return on Equity-9.95% Return on Assets-4.61% Debt Debt-to-Equity Ratio6.66 Current Ratio3.80 Quick Ratio2.29 Sales & Book Value Annual SalesC$17.52 million Price / Sales0.49 Cash FlowC$0.36 per share Price / Cash Flow1.20 Book ValueC$0.94 per share Price / Book0.46Miscellaneous Outstanding Shares19,540,000Free FloatN/AMarket CapC$8.50 million OptionableNot Optionable Beta1.65 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Serge Verreault B.A.M.B.A., President, CEO & DirectorMr. Jose DaRocha C.A.CPA, Chief Financial OfficerMr. Francois LafortuneExecutive VP & GMKey CompetitorsAleafia HealthTSE:AHKhiron Life SciencesCVE:KHRNValeo PharmaTSE:VPHVoyageur PharmaceuticalsCVE:VMDelta 9 CannabisTSE:DNView All CompetitorsInsidersJose DarochaBought 33,500 shares on 12/22/2023Total: C$14,405.00 ($0.43/share) CTX Stock Analysis - Frequently Asked Questions How have CTX shares performed in 2024? Crescita Therapeutics' stock was trading at C$0.49 at the beginning of the year. Since then, CTX stock has decreased by 11.2% and is now trading at C$0.44. View the best growth stocks for 2024 here. What other stocks do shareholders of Crescita Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crescita Therapeutics investors own include CBTX (CBTX), West Japan Railway (WJRYY), FAT Brands (FAT), Laredo Petroleum (LPI), Contango Oil & Gas (MCF), North American Construction Group (NOA), Spirit AeroSystems (SPR), Tesla (TSLA), Wells Fargo & Company (WFC) and Agellan Commercial Real Estate Invtmt TR (ACR.UN). How do I buy shares of Crescita Therapeutics? Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CTX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescita Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.